Several strongylophorines have been into the spotlight due to the reports on their versatile modes of action towards cancer cells, acting as Rho-dependent inhibitors of tumor cell invasion [278], proteasome inhibitors [279], and as inhibitors of the HIF-1 transcriptional pathway [280]. Here, HIF1A is linked to cancer.